Real World Data for Small and Medium Size Companies: they can turn the disadvantage to a winning position.
Many small and medium-sized companies are at a disadvantage due to their limited use of Real World Evidence (RWE) compared to larger companies. But this doesn't have to be the case.
Pharmacovigilance: The risk-benefit balance of anti-amyloid antibodies for treatment of dementia
We have published a review in the British Journal of Clinical Pharmacology about the safety and effectiveness of anti-amyloid antibodies for the treatment of dementia.